Dr. Luisa Salter-Cid

Background

Dr. Salter-Cid brings over 20 years of outstanding leadership experience in the biotech and pharmaceutical industries, with deep expertise in Immunology and Immuno-Oncology where she has established a prolific track record of translating scientific insights into clinical-stage assets. She holds a Ph.D. in Immunology from the University of Miami Miller School of Medicine, an M.S. in Biology from Florida International University, and completed a Post-Doctoral Fellowship at Scripps Research Institute in San Diego, CA.

Career History

• Scientific Advisor, Harbour BioMed (June 2026–present)
• Venture Partner, Osage University Partners (OUP)
• Chief Scientific Officer, Pioneering Medicines, Flagship Pioneering (2021–2026)
• Chief Scientific Officer, Gossamer Bio (2018–2021)
• Vice President and Head of Immunology, Small Molecule Immuno-Oncology, and Genomics Discovery, Bristol Myers Squibb (2005–2018, 13 years)

Notable Achievements

During her 13 years at BMS, she led teams that advanced more than 20 compounds into clinical development, including Deucravacitinib. She was Chair of the Immunoscience Target Science Team and a core member of Early Development, Strategy and Licensing teams for both Immunology and Immuno-Oncology, and was the scientific lead on several of BMS' acquisitions and licensing deals. She has authored over 80 publications and patents and is a member of the Scientific Advisory Board of Anaptys, Ambrx and Ventyx Bio.

What Dr. Salter-Cid Could Bring to Harbour BioMed

Dr. Salter-Cid's appointment as Scientific Advisor positions her to leverage her extensive translational immunology expertise and track record advancing clinical-stage assets to help Harbour BioMed expand its pipeline of antibody therapeutics. Her leadership at BMS and Gossamer Bio in building immunology and immuno-oncology portfolios, combined with her recent venture capital experience at Osage University Partners, equips her to advise on both scientific strategy and partnership opportunities. Her experience advancing 20+ compounds to the clinic and managing acquisitions and licensing deals suggests she can provide strategic insights as Harbour BioMed scales its differentiated antibody technology platform and discovery programs in immunology and oncology.